| abstract |
Compounds of the general formula in which R1 denotes halogen, halogen- (C1-C6) -alkyl, cyan, (C1-C6) -alkoxy or halogen- (C1-C6) -alkoxy, R21, R22, R23 and R24 are independently selected from the group consisting of hydrogen, (C1-C6) -alkyl, halogen, halogen- (C1-C6) -alkyl, hydroxy, (C1-C6) -alkoxy or -CHO, R3 denotes hydrogen or (C1-C3) -alkyl, R4, R5 independently of one another are selected from the group consisting of hydrogen, (C1-C6) -alkyl, (C1-C6) -alkoxy or -COO (C1-C6) -alkyl, or R4 and R5 together with the C-atom to which they are attached form a (C3-C7) -cycloalkyl ring, R6 denotes -CO-NR7R8, -COO (C1-C6) -alkyl, or -NHC (O) R, R7 and R8 independently of the other are selected from the group consisting of hydrogen, (C1-C6) -alkyl, NH2 or hydroxy, R represents hydrogen or (C1-S6) -alkyl, n is 0, 1, 2 or 3, X represents -CHRO, -OCHR-, -CH2S-, -SCH2-, -CH2CH2-, -CH = CH- or -C≡C-, and their pharmaceutically active acid addition salts. The application contains 15 more claims a. |